Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03052608
Registration number
NCT03052608
Ethics application status
Date submitted
20/01/2017
Date registered
14/02/2017
Date last updated
20/02/2024
Titles & IDs
Public title
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Query!
Scientific title
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Query!
Secondary ID [1]
0
0
2016-003315-35
Query!
Secondary ID [2]
0
0
B7461006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Non-Small-Cell Lung
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lorlatinib
Treatment: Drugs - Crizotinib
Experimental: Lorlatinib - Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
Active Comparator: Crizotinib - Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
Treatment: Drugs: Lorlatinib
ALK-positive NSCL treatment
Treatment: Drugs: Crizotinib
ALK-positive NSCL treatment
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to the date of the first documentation of progressive disease as assessed by the independent radiologist or death due to any cause, whichever occurred first. PFS (in months) was calculated as (date of event or censoring-randomization+1)/30.4375. Progressive disease is defined per RECIST version 1.1, as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.
Query!
Timepoint [1]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death or censoring - start date +1)/30.4375. Participants last known to be alive were censored at date of last contact.
Query!
Timepoint [1]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [2]
0
0
Progression-Free Survival (PFS) Based on Investigator's Assessment
Query!
Assessment method [2]
0
0
PFS was defined as the time from randomization to the date of the first documentation of progressive disease as assessed by investigator or death due to any cause, whichever occurred first. PFS (in months) was calculated as (date of event or censoring-randomization+1)/30.4375. Progressive disease is defined per RECIST version 1.1, as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.
Query!
Timepoint [2]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [3]
0
0
Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment
Query!
Assessment method [3]
0
0
ORR was the percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Query!
Timepoint [3]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [4]
0
0
Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment
Query!
Assessment method [4]
0
0
ORR was the percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Query!
Timepoint [4]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [5]
0
0
Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment
Query!
Assessment method [5]
0
0
IC-ORR was the percentage of participant with intracranial objective response of complete response (CR) or partial response (PR) based on intracranial disease in the subset of participants with at least 1 intracranial lesion per RECIST version 1.1 (modified) recorded from randomization until disease progression or start of new anti-cancer therapy. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Query!
Timepoint [5]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [6]
0
0
Intracranial Time to Progression (IC-TTP) Based on BICR Assessment
Query!
Assessment method [6]
0
0
IC-TTP based on BICR assessment was defined as the time from date of randomization to the date of the first documentation of progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.
Query!
Timepoint [6]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [7]
0
0
Duration of Response (DR) Based on BICR Assessment
Query!
Assessment method [7]
0
0
DR was defined, for participants with a confirmed objective response (OR) of complete response (CR) or partial response (PR) per RECIST version 1.1, as the time from the first documentation of OR to the first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.
Query!
Timepoint [7]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [8]
0
0
Intracranial Duration of Response (IC-DR) Based on BICR Assessment
Query!
Assessment method [8]
0
0
IC-DR was defined, for participants with a confirmed intracranial objective response (OR) of complete response (CR) or partial response (PR) per RECIST version 1.1, as the time from the first documentation of intracranial OR to the first documentation of intracranial progressive disease (PD) or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.
Query!
Timepoint [8]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [9]
0
0
Time to Tumor Response (TTR) Based on BICR Assessment
Query!
Assessment method [9]
0
0
TTR based on BICR assessment was defined, for participants with a confirmed objective response, as the time from the date of randomization to the first documentation of objective response (complete response or partial response) which was subsequently confirmed. Complete response was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). Partial response was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Query!
Timepoint [9]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [10]
0
0
Intracranial Time to Tumor Response (IC-TTR) Based on BICR Assessment
Query!
Assessment method [10]
0
0
IC-TTR was defined, for participants with a confirmed intracranial objective response, as the time from the date of randomization to the first documentation of intracranial objective response (complete response or partial response) which was subsequently confirmed. Complete response was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). Partial response was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Query!
Timepoint [10]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [11]
0
0
PFS2 Based on Investigator's Assessment
Query!
Assessment method [11]
0
0
PFS2 was defined as the time from randomization to the date of progression of disease on first subsequent systemic anti-cancer therapy, or death from any cause, whichever occurred first
Query!
Timepoint [11]
0
0
From time of Study Start up to 45 months
Query!
Secondary outcome [12]
0
0
Number of Participants With Treatment-Emergent Adverse Events (AEs; All-Causality and Treatment-Related)
Query!
Assessment method [12]
0
0
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs in the table below were treatment-emergent AEs. Grade 3 and 4 AEs in the table below indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE. Treatment-related AEs were determined by investigators.
Query!
Timepoint [12]
0
0
From time of Study Start up to 33 months
Query!
Secondary outcome [13]
0
0
Number of Participants With Changes in Hematology Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4
Query!
Assessment method [13]
0
0
Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.
Query!
Timepoint [13]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [14]
0
0
Number of Participants With Changes in Chemistry Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4
Query!
Assessment method [14]
0
0
Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.
Query!
Timepoint [14]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [15]
0
0
Number of Participants With Changes in Lipid Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4
Query!
Assessment method [15]
0
0
Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.
Query!
Timepoint [15]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [16]
0
0
Number of Participant With Vital Signs and Body Weight Data Meeting Pre-defined Criteria
Query!
Assessment method [16]
0
0
Vital signs data included pulse, systolic blood pressure, and diastolic blood pressure. Measurements were only provided once per timepoint. If multiple assessments were provided per timepoint, the maximum value were used for reporting. The pre-defined criteria of vital sign and body weight data were as follows: maximum pulse rate >120 beats per minute (bpm); minimum pulse rate <50 bpm; maximum increase in pulse rate =30 bpm; maximum decrease in pulse rate =30 bpm; increase in systolic blood Pressure =40 mmHg; decrease in systolic blood pressure =40 mmHg; decrease in systolic blood pressure =60 mmHg; increase in diastolic blood pressure =20 mmHg; decrease in diastolic blood pressure =20 mmHg; decrease in diastolic blood pressure =40 mmHg; increase in body weight =10%; increase in body weight =20%; decrease in body weight =10%.
Query!
Timepoint [16]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [17]
0
0
Number of Participant With Maximum Increase From Baseline in Electrocardiogram (ECG) Data Meeting Pre-defined Criteria
Query!
Assessment method [17]
0
0
Baseline was defined as the last assessment performed on or prior to date of the first dose of study treatment. Triplicate ECGs were collected in the study and the average of the replicate assessments were used for summary analysis. The pre-defined criteria of ECG data were as follows: change from baseline in QTcF =60 msec, =30 msec but <60 msec, <30 msec; change from baseline in QTcB =60 msec, =30 msec but <60 msec, <30 msec; PR change =50% if absolute baseline value was <200 msec; PR change =25% if absolute baseline value was =200 msec; QRS change =50% if absolute baseline value was <100 msec; QRS change =25% if absolute baseline value was =100 msec.
Query!
Timepoint [17]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [18]
0
0
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage
Query!
Assessment method [18]
0
0
In this outcome measure, baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. Decrease from baseline was an absolute difference between baseline and observed value.
Query!
Timepoint [18]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [19]
0
0
Change From Baseline in Total Scores of Beck Depression Inventory (BDI)-II (Mood Assessment) Across Time
Query!
Assessment method [19]
0
0
BDI-II (Mood Assessment) is a 21 item self-reported scale, with each item rated by participants on a 4-point scale (ranging from 0-3). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike pessimism, poor concentration) as well as somatic signs (appetite, sleep, fatigue, libido). Scores were obtained by adding up the total points from the series of answers. The total score ranged from 0 to 63, with higher total scores indicating more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.
Query!
Timepoint [19]
0
0
Baseline, Cycle 2 Day 1 (C2D1), C3D1, C4D1, C5D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1, C22D1, C24D1, C26D1, C28D1, C30D1, C32D1, C34D1, C36D1, C38D1 and End of Treatment
Query!
Secondary outcome [20]
0
0
Number of Participants With Suicidal Ideation and Suicidal Behavior Across Time
Query!
Assessment method [20]
0
0
Suicidal ideation and behaviors were assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation, and deterrents), all of which are significantly predictive of completed suicide.
Query!
Timepoint [20]
0
0
Baseline, Cycle 2 Day 1 (C2D1), C3D1, C4D1, C5D1, C6D1, C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1, C22D1, C24D1, C26D1, C28D1, C30D1, C32D1, C34D1, C36D1, C38D1 and End of Treatment
Query!
Secondary outcome [21]
0
0
Change From Baseline in Global Quality of Life (QOL), Functional Scales and Symptoms Scales as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) During Overall Treatment
Query!
Assessment method [21]
0
0
The EORTC QLQ C30 consists of 30 questions and includes 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assess additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and financial impact. All scales and single item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.
Query!
Timepoint [21]
0
0
From Baseline up to Cycle 38 Day 1
Query!
Secondary outcome [22]
0
0
Change From Baseline in Lung Cancer Symptoms as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) During Overall Treatment
Query!
Assessment method [22]
0
0
The EORTC QLQ LC13 consists of 13 questions and includes 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, haemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The scale scores rang from 0 to 100, with higher scores indicating higher ("worse") level of symptoms.
Query!
Timepoint [22]
0
0
From Baseline up to Cycle 38 Day 1
Query!
Secondary outcome [23]
0
0
Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Visual Analogue Scale (VAS) Across Time
Query!
Assessment method [23]
0
0
The EuroQol EQ-5D-5L is a participant-completed questionnaire designed to assess health status. There are 2 components to the EuroQol EQ-5D-5L: a descriptive system in which individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a VAS. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) and higher scores indicate better health state.
Query!
Timepoint [23]
0
0
Baseline, Day 1 of all cycles from Cycle 2 to Cycle 38, and End of Treatment
Query!
Secondary outcome [24]
0
0
Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Index Across Time
Query!
Assessment method [24]
0
0
The EuroQol EQ-5D-5L is a participant-completed questionnaire designed to assess health status. There are 2 components to the EuroQol EQ-5D-5L: a descriptive system in which individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a VAS in which participants rate their overall health status from 0 (worst imaginable) to 100 (best imaginable). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
Query!
Timepoint [24]
0
0
Baseline, Day 1 of all cycles from Cycle 2 to Cycle 38, and End of Treatment
Query!
Secondary outcome [25]
0
0
Time to Deterioration (TTD) in Participant Reported Pain in Chest, Dyspnea, or Cough From QLQ-LC13
Query!
Assessment method [25]
0
0
The EORTC QLQ LC13 consists of 13 questions and includes 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, haemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The scale scores rang from 0 to 100, with higher scores indicating higher ("worse") level of symptoms. TTD in pain in chest, dyspnea, or cough was defined as the time from randomization to the first time the participant's score showed a 10 point or greater increase after baseline in any of the 3 symptoms. TTD in months was calculated as (date of deterioration or censoring - randomization date +1)/30.4375.
Query!
Timepoint [25]
0
0
From Baseline up to 33 months
Query!
Secondary outcome [26]
0
0
Number of Participant With ALK Domain Mutation in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
Query!
Assessment method [26]
0
0
The analysis of anaplastic lymphoma kinase (ALK) domain mutation in plasma CNA was performed by next-generation sequencing (NGS) and the number of participants with one or more ALK mutations at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here.
Query!
Timepoint [26]
0
0
at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
Query!
Secondary outcome [27]
0
0
Number of Participant With ALK Fusion Variant in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
Query!
Assessment method [27]
0
0
The analysis of ALK fusion variant in plasma CNA was performed by NGS and the number of participants with fusion variants at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here. In the table below, EML4-ALK is the abbreviation of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase.
Query!
Timepoint [27]
0
0
at Screening, Cycle 2 Day 1 and Cycle 7 Day 1
Query!
Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic
ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously
irradiated. CNS metastases allowed if asymptomatic and not currently requiring
corticosteroid treatment.
- Availability of an archival FFPE tissue specimen.
- No prior systemic NSCLC treatment.
- ECOG PS 0, 1, or 2.
- Age =18 years .
- Adequate Bone Marrow, Liver, Renal, Pancreatic Function
- Negative pregnancy test for females of childbearing potential
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Spinal cord compression unless good pain control attained
- Major surgery within 4 weeks prior to randomization.
- Radiation therapy within 2 weeks prior to randomization, including stereotactic or
partial brain irradiation. Whole brain irradiation within 4 weeks prior to
randomization
- Active bacterial, fungal, or viral infection
- Clinically significant cardiovascular disease, active or within 3 months prior to
enrollment. Ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation,
bradycardia or congenital long QT syndrome
- Predisposing characteristics for acute pancreatitis in the last month prior to
randomization.
- History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial
fibrosis or interstitial lung disease
- Active malignancy (other than NSCLC, non melanoma skin cancer, in situ cervical
cancer, papillary thyroid cancer, LCIS/DCIS of the breast, or localized prostate
cancer) within the last 3 years prior to randomization.
- Concurrent use of any of the following food or drugs within 12 days prior to the first
dose of lorlatinib or crizotinib.
1. known strong CYP3A inhibitors .
2. known strong CYP3A inducers
3. known P gp substrates with a narrow therapeutic index
- Concurrent use of CYP3A substrates with narrow therapeutic indices within 12 days
prior to the first dose of lorlatinib or crizotinib.
- Other severe acute or chronic medical or psychiatric condition, including recent or
active suicidal ideation or behavior, or laboratory abnormality that may increase the
risk associated with study participation or interfere with the interpretation of study
results
- Investigational site staff members directly involved in the conduct of the study and
their family members, or Pfizer employees, including their family members, directly
involved in the conduct of the study.
- Participation in other studies involving investigational drug(s) within 2 weeks prior
to study entry and/or during study participation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/04/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2028
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
296
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Bendigo Day Surgery Collection Centre and Laboratory - Bendigo
Query!
Recruitment hospital [2]
0
0
Bendigo Medical Imaging, Bendigo Hospital - Bendigo
Query!
Recruitment hospital [3]
0
0
Melbourne Pathology - Bendigo
Query!
Recruitment hospital [4]
0
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3550 - Bendigo
Query!
Recruitment postcode(s) [2]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Tennessee
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Washington
Query!
Country [6]
0
0
Argentina
Query!
State/province [6]
0
0
Buenos Aires
Query!
Country [7]
0
0
Argentina
Query!
State/province [7]
0
0
Caba
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Charleroi
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Ontario
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Quebec
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Beijing
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Jilin
Query!
Country [13]
0
0
China
Query!
State/province [13]
0
0
Shanghai
Query!
Country [14]
0
0
China
Query!
State/province [14]
0
0
Zhejiang
Query!
Country [15]
0
0
China
Query!
State/province [15]
0
0
Guangzhou
Query!
Country [16]
0
0
Czechia
Query!
State/province [16]
0
0
Olomouc
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Praha 2
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Aquitaine
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Chevilly Larue
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Le Mans
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Marseille cedex 09
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Marseille cedex 20
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Paris
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Rennes cedex 9
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Suresnes
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Toulouse Cedex 9
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Toulouse cedex 9
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Villejuif
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Dresden
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Heidelberg
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Homburg - Saar
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Regensburg
Query!
Country [33]
0
0
Hong Kong
Query!
State/province [33]
0
0
Hong Kong
Query!
Country [34]
0
0
India
Query!
State/province [34]
0
0
Haryana
Query!
Country [35]
0
0
India
Query!
State/province [35]
0
0
Karnataka
Query!
Country [36]
0
0
India
Query!
State/province [36]
0
0
Maharashtra
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
CT
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
MB
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
MI
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
PG
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
PN
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
PR
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
RM
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Napoli
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Ravenna
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Aichi
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Ehime
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Fukuoka
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Hokkaido
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Ishikawa
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Kanagawa
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Miyagi
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Osaka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Shizuoka
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Tokyo
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Yamaguchi
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Koto-ku, Tokyo
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Niigata
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Okayama
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Tokushima
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Wakayama
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Gyeonggi-do
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Seoul
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Ulsan
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Aguascalientes
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Distrito Federal
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Groningen
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Gdansk
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Poznan
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Szczecin
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Warszawa
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Kursk Region
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
OMSK Region
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Saint-petersburg
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Kursk
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Moscow
Query!
Country [77]
0
0
Singapore
Query!
State/province [77]
0
0
Singapore
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Barcelona
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Canarias
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Madrid
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Navarra
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
A Coruna
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Girona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Valencia
Query!
Country [85]
0
0
Taiwan
Query!
State/province [85]
0
0
Taiwan ROC
Query!
Country [86]
0
0
Taiwan
Query!
State/province [86]
0
0
Kaohsiung
Query!
Country [87]
0
0
Taiwan
Query!
State/province [87]
0
0
Taichung
Query!
Country [88]
0
0
Taiwan
Query!
State/province [88]
0
0
Taipei
Query!
Country [89]
0
0
Turkey
Query!
State/province [89]
0
0
Adana
Query!
Country [90]
0
0
Turkey
Query!
State/province [90]
0
0
Istanbul
Query!
Country [91]
0
0
Turkey
Query!
State/province [91]
0
0
Izmir
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Suffolk
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
WEST Midlands
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to
crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC
patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to
overall survival in the same population
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03052608
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03052608
Download to PDF